Collagen copolymer toric posterior chamber phakic intraocular lens for myopic astigmatism One-year follow-up

PURPOSE: To assess the predictability, efficacy, safety, and stability of collagen copolymer toric phakic intraocular lens (pIOL) implantation to correct moderate to high myopic astigmatism SETTING: Fernandez-Vega Ophthalmological Institute, Oviedo, Spain METHODS: This study comprised eyes that had implantation of a toric Intraocular Collamer Lens for moderate to high myopic astigmatism The uncorrected (UDVA) and corrected (CDVA) distance visual acuities. refraction, pIOL vault, and adverse events were evaluated over 12 months RESULTS: Preoperatively, the mean sphere in the 55 eyes was -4.65 diopters (D) +/- 3.02 (SD) (range -050 to -12.50 D) and the mean cylinder, -3.03 +/- 0.79 D (range -1 25 to -4.00 D) At 12 months, the mean Snellen decimal UDVA was 0 80 +/- 0 20 and the mean CDVA, 0 85 +/- 0 18; 62.0% of eyes had a CDVA of 20/20 More than 500% of eyes gained 1 or more lines of CDVA. The treatment was highly predictable for spherical equivalent (SE) (r(2) = 0 99) and astigmatic components J0 (r(2) = 0 97) and J45 (r(2) = 0 99) Of the eyes, 94.5% were within +/- 0.50 D of the attempted SE and all were within +/- 1.00 D For J0, 94.5% of eyes were within +/- 0.50 D and for J45, 98 2% of eyes; all eyes were within +/- 1.00 D The efficacy index was 0 95 at 3 months and 1.08 at 1 year. CONCLUSIONS: The UDVA and CDVA with tom pIOLs were good and highly stable over 12 months, confirming the procedure is safe, predictable, and effective for correction of moderate to high astigmatic